KEYNOTE-059, trial summary

A randomised clinical trial investigating the effect of pembrolizumab versus nil in


NCT02335411    JAMA Oncol 2018;4:e180013  

Studied treatment
Control treatment

Group sizes-9 / -9

Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design Single-arm study

EndpointX1N1X0N0TE95% CI OS - -9 - -9 no data PFS - -9 - -9 no data ORR - -9 - -9 no data0,22,01,0

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Ros Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018;4:e180013     [PMID: 29543932]   link to pdf   add to Mendeley  


ASCO post record NCT02335411

Registering number NCT02335411 (see trial on
Code Name